Zynyz®

Understanding Zynyz®

Zynyz® (retifanlimab-dlwr) is a prescription medicine indicated, in specific treatment settings and regimens, for the treatment of adult patients with squamous cell carcinoma of the anal canal (SCAC) and Merkel cell carcinoma (MCC):

• In combination with carboplatin and paclitaxel, for the first-line treatment of adult patients with inoperable locally recurrent or metastatic SCAC.
• As a single agent, for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.
• For the treatment of adult patients with metastatic or recurrent locally advanced MCC.

Zynyz® is a programmed death receptor-1 (PD-1)-blocking antibody administered by intravenous infusion. Retifanlimab-dlwr is a humanized IgG4 kappa monoclonal antibody.

How Zynyz® Works:

• Targets the PD-1 receptor: Zynyz® contains retifanlimab-dlwr, a PD-1-blocking antibody that binds to the PD-1 receptor found on T cells.
• Blocks the PD-1 pathway: Retifanlimab-dlwr blocks the interaction of PD-1 with its ligands, PD-L1 and PD-L2.
• Potentiates T-cell activity: Binding of PD-L1 and PD-L2 to the PD-1 receptor inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Retifanlimab-dlwr potentiates T-cell activity.

FDA Approval:

For more information, please visit the Zynyz® patient website. Speak with your healthcare provider to determine if Zynyz® is the right treatment option for you.